These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35033554)

  • 1. Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4 signaling.
    Xu F; Wang J; Wang P; Hou T; Zhou H; Zhao Y; Wang J; Liu Y; Liang X
    Eur J Pharmacol; 2022 Feb; 917():174760. PubMed ID: 35033554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
    Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
    World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-3 polyunsaturated fatty acids protect human hepatoma cells from developing steatosis through FFA4 (GPR120).
    Kang S; Huang J; Lee BK; Jung YS; Im E; Koh JM; Im DS
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Feb; 1863(2):105-116. PubMed ID: 29126901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-3 Polyunsaturated Fatty Acids Protect against Alcoholic Liver Steatosis by Activating FFA4 in Kupffer Cells.
    Kang S; Koh JM; Im DS
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
    Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
    J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
    Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
    Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.
    Xu L; Kim JK; Bai Q; Zhang X; Kakiyama G; Min HK; Sanyal AJ; Pandak WM; Ren S
    Mol Pharmacol; 2013 Mar; 83(3):648-58. PubMed ID: 23258548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
    Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotundic acid ameliorates non-alcoholic steatohepatitis via SREBP-1c/ SCD1 signaling pathway and modulating gut microbiota.
    Liu HJ; Cao ST; Wen BY; Han X; Li Y; Li S; Li J; Zhang L
    Int Immunopharmacol; 2021 Oct; 99():108065. PubMed ID: 34426119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
    Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
    J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X; Liu Z; Wang J
    Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
    Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
    Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.
    Lee JM; Gang GT; Kim DK; Kim YD; Koo SH; Lee CH; Choi HS
    J Biol Chem; 2014 Jan; 289(2):1079-91. PubMed ID: 24265317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro.
    Wei D; Wu S; Liu J; Zhang X; Guan X; Gao L; Xu Z
    Can J Physiol Pharmacol; 2021 Aug; 99(8):775-785. PubMed ID: 33290156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1.
    Ziamajidi N; Khaghani S; Hassanzadeh G; Vardasbi S; Ahmadian S; Nowrouzi A; Ghaffari SM; Abdirad A
    Food Chem Toxicol; 2013 Aug; 58():198-209. PubMed ID: 23603006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 7
    Huang J; Lee SJ; Kang S; Choi MH; Im DS
    J Pharmacol Exp Ther; 2020 Jul; 374(1):142-150. PubMed ID: 32341017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
    Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
    Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
    Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
    J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
    Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
    Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.